Loading...

Vito Michele Campese, MD

TitleProfessor of Medicine
InstitutionUniversity of Southern California
DepartmentMedicine
AddressIRD 804 2020 Zonal Ave.
Off Campus
Los Angeles CA 90089-9520
Phone+1 323 226 7337
vCardDownload vCard

    Collapse Biography 
    Collapse Awards and Honors
    1988The Domenico Cotugno Medal and Award in Nephrology
    1991The Regione Puglia Targa d'Oro Award for Contribution to Science
    Rotary Club International2002Rotary Club Contribution to Science Award
    2006University Kidney Disease Research Disease
    The Italians Society of Nephrology 2007Honorary Membership

    Collapse Overview 
    Collapse Overview
    A native of Bari, Italy, Dr. Campese graduated medical school summa cum laude before coming to the Keck School of Medicine on a fellowship in 1974. Since his time at USC, Dr. Campese has established himself as one on the most prominent nephrologists in the field and currently heads Keck’s division of Nephrology.

    In addition to his numerous academic and administrative appointments, Dr. Campese is a former president of the Italian-American Society of Nephrologists and is currently a member of the Program Committee on the Council on High Blood Pressure Research for the American Heart Association.


    Collapse Research 
    Collapse Research Activities and Funding
    Oxidative Stress And Sympathetic Nerve Activity
    NIH/NHLBI R01HL071792Jan 24, 2003 - Dec 31, 2008
    Role: Principal Investigator
    KIDNEY STUDY IN HYPERTENSIVE BLACK MEN AND WOMEN
    NIH/NHLBI R01HL047881Sep 30, 1991 - Jul 31, 1996
    Role: Principal Investigator
    SODIUM AND CALCIUM METABOLISM IN PREHYPERTENSIVE STATE
    NIH/NHLBI R01HL035629Sep 30, 1988 - Sep 29, 1992
    Role: Principal Investigator

    Collapse ORNG Applications 
    Collapse Clinical Trials
    Collapse Websites
    Collapse In The News

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
    List All   |   Timeline
    1. Campese V, Adenuga G. Renovascular disease: Is there still a role for revascularization??. Clin Nephrol. 2018 Apr; 89(4):229-240. PMID: 29493505.
      View in: PubMed
    2. Ku E, Bakris G, Johansen KL, Lin F, Sarnak MJ, Campese V, Jamerson K, Gassman JJ, Smogorzewski M, Hsu CY. Acute Declines in Renal Function during Intensive BP Lowering: Implications for Future ESRD Risk. J Am Soc Nephrol. 2017 Sep; 28(9):2794-2801. PMID: 28473636.
      View in: PubMed
    3. Campese V. Con: Mesoamerican nephropathy: is the problem dehydration or rehydration? Nephrol Dial Transplant. 2017 04 01; 32(4):603-606. PMID: 28407133.
      View in: PubMed
    4. Campese V. Opponent's comments. Nephrol Dial Transplant. 2017 04 01; 32(4):602-603. PMID: 28407136.
      View in: PubMed
    5. Maarek JM, Rubinstein EH, Guo Y, Lane CJ, Campese V, Holschneider DP. Measurement of Cardiac Output and Blood Volume During Hemodialysis with Fluorescent Dye Dilution Technique. Ann Biomed Eng. 2017 03; 45(3):580-591. PMID: 27539225.
      View in: PubMed
    6. Campese V. Predictors of blood pressure response to spironolactone. J Hypertens. 2016 May; 34(5):845-7. PMID: 27027381.
      View in: PubMed
    7. Campese V. The Mesoamerican nephropathy: a regional epidemic of chronic kidney disease? Nephrol Dial Transplant. 2016 Mar; 31(3):335-6. PMID: 26801771.
      View in: PubMed
    8. Campese V. Statins and the kidney: friend or foe? Lancet Diabetes Endocrinol. 2015 Mar; 3(3):161-2. PMID: 25660357.
      View in: PubMed
    9. Campese V, Lakdawala R. The Challenges of Blood Pressure Control in Dialysis Patients. Recent Adv Cardiovasc Drug Discov. 2015; 10(1):34-59. PMID: 26567722.
      View in: PubMed
    10. Campese V. Left ventricular function and chronic kidney disease: how soon does it start? Nephrol Dial Transplant. 2014 Nov; 29(11):1989-91. PMID: 25209365.
      View in: PubMed
    11. Amarenco P, Callahan A, Campese V, Goldstein LB, Hennerici MG, Messig M, Sillesen H, Welch KM, Wilson DJ, Zivin JA. Effect of high-dose atorvastatin on renal function in subjects with stroke or transient ischemic attack in the SPARCL trial. Stroke. 2014 Oct; 45(10):2974-82. PMID: 25147328.
      View in: PubMed
    12. Campese V. Reply to 'resistant hypertension and central aortic pressure'. J Hypertens. 2014 Mar; 32(3):699. PMID: 24477099.
      View in: PubMed
    13. Campese V. Dyslipidemia and progression of kidney disease: role of lipid-lowering drugs. Clin Exp Nephrol. 2014 Apr; 18(2):291-5. PMID: 24535025.
      View in: PubMed
    14. Campese V. Pathophysiology of resistant hypertension in chronic kidney disease. Semin Nephrol. 2014; 34(5):571-6. PMID: 25416666.
      View in: PubMed
    15. Campese V. Interventional hypertension: a new hope or a new hype? The need to redefine resistant hypertension. J Hypertens. 2013 Nov; 31(11):2118-21; discussion 2122. PMID: 24077243.
      View in: PubMed
    16. Schlaich MP, Schmieder RE, Bakris G, Blankestijn PJ, Böhm M, Campese V, Francis DP, Grassi G, Hering D, Katholi R, Kjeldsen S, Krum H, Mahfoud F, Mancia G, Messerli FH, Narkiewicz K, Parati G, Rocha-Singh KJ, Ruilope LM, Rump LC, Sica DA, Sobotka PA, Tsioufis C, Vonend O, Weber MA, Williams B, Zeller T, Esler MD. International expert consensus statement: Percutaneous transluminal renal denervation for the treatment of resistant hypertension. J Am Coll Cardiol. 2013 Dec 03; 62(22):2031-45. PMID: 24021387.
      View in: PubMed
    17. Koya D, Campese V. Statin use in patients with diabetes and kidney disease: the Japanese experience. J Atheroscler Thromb. 2013; 20(5):407-24. PMID: 23518468.
      View in: PubMed
    18. Ku E, Campese V. Is lipid management effective for all stages of CKD?. Blood Purif. 2013; 35(1-3):26-30. PMID: 23343543.
      View in: PubMed
    19. Park J, Middlekauff HR, Campese V. Abnormal sympathetic reactivity to the cold pressor test in overweight humans. Am J Hypertens. 2012 Dec; 25(12):1236-41. PMID: 22895452; PMCID: PMC3577042.
    20. Park J, Campese V. Resistant hypertension and obstructive sleep apnea in end-stage renal disease. J Hypertens. 2012 May; 30(5):880-1. PMID: 22495130.
      View in: PubMed
    21. Ku E, Ananthapanyasut W, Campese V. IgA nephropathy in a patient with ulcerative colitis, Graves' disease and positive myeloperoxidase ANCA. Clin Nephrol. 2012 Feb; 77(2):146-50. PMID: 22257545.
      View in: PubMed
    22. Campese V, Ku E, Bigazzi R, Bianchi S. Do HMG-CoA reductase inhibitors improve kidney function? The saga continues. J Nephrol. 2011 Sep-Oct; 24(5):550-3. PMID: 21887675.
      View in: PubMed
    23. Campese V, Ku E, Park J. Sympathetic renal innervation and resistant hypertension. Int J Hypertens. 2011 Jan 20; 2011:814354. PMID: 21331158; PMCID: PMC3034934.
    24. Gill IS, Eisenberg MS, Aron M, Berger A, Ukimura O, Patil MB, Campese V, Thangathurai D, Desai MM. "Zero ischemia" partial nephrectomy: novel laparoscopic and robotic technique. Eur Urol. 2011 Jan; 59(1):128-34. PMID: 20971550.
      View in: PubMed
    25. Campese V, Schneider EL. Reevaluating the use of antihypertensive medications, a first step toward reducing polypharmacy in very old patients. J Clin Hypertens (Greenwich). 2010 Aug; 12(8):621-4. PMID: 20695939.
      View in: PubMed
    26. Lu Y, Ku E, Campese V. Aldosterone in the pathogenesis of chronic kidney disease and proteinuria. Curr Hypertens Rep. 2010 Aug; 12(4):303-6. PMID: 20596805.
      View in: PubMed
    27. Schneider EL, Campese V. Adverse drug responses: An increasing threat to the well-being of older patients: Comment on "Development and validation of a score to assess risk of adverse drug reactions among in-hospital patients 65 years or older". Arch Intern Med. 2010 Jul 12; 170(13):1148-9. PMID: 20625023.
      View in: PubMed
    28. Campese V. Oxidative stress and sympathetic activity in hypertension. Am J Hypertens. 2010 May; 23(5):456. PMID: 20404802.
      View in: PubMed
    29. Bianchi S, Bigazzi R, Campese V. Intensive versus conventional therapy to slow the progression of idiopathic glomerular diseases. Am J Kidney Dis. 2010 Apr; 55(4):671-81. PMID: 20097461.
      View in: PubMed
    30. Cioni A, Sordini C, Cavallini I, Bigazzi R, Campese V. Angiotensin receptor blocker telmisartan improves insulin sensitivity in peritoneal dialysis patients. Perit Dial Int. 2010 Jan-Feb; 30(1):66-71. PMID: 20056982.
      View in: PubMed
    31. Ku E, Campese V. Aldosterone and hypertension in African Americans. Am J Hypertens. 2009 Dec; 22(12):1234. PMID: 19924116.
      View in: PubMed
    32. Ku E, Park J, Vidhun J, Campese V. The hazards of dual renin-angiotensin blockade in chronic kidney disease. Arch Intern Med. 2009 Jun 08; 169(11):1015-8. PMID: 19506167.
      View in: PubMed
    33. Ku E, Nobakht N, Campese V. Lixivaptan: a novel vasopressin receptor antagonist. Expert Opin Investig Drugs. 2009 May; 18(5):657-62. PMID: 19379124.
      View in: PubMed
    34. Ku E, Campese V. Role of aldosterone in the progression of chronic kidney disease and potential use of aldosterone blockade in children. Pediatr Nephrol. 2009 Dec; 24(12):2301-7. PMID: 19347366.
      View in: PubMed
    35. Bai Y, Jabbari B, Ye S, Campese V, Vaziri ND. Regional expression of NAD(P)H oxidase and superoxide dismutase in the brain of rats with neurogenic hypertension. Am J Nephrol. 2009; 29(5):483-92. PMID: 19047792; PMCID: PMC2821947.
    36. Park J, Campese V, Nobakht N, Middlekauff HR. Differential distribution of muscle and skin sympathetic nerve activity in patients with end-stage renal disease. J Appl Physiol (1985). 2008 Dec; 105(6):1873-6. PMID: 18845779; PMCID: PMC2612470.
    37. Park J, Campese V, Middlekauff HR. Exercise pressor reflex in humans with end-stage renal disease. Am J Physiol Regul Integr Comp Physiol. 2008 Oct; 295(4):R1188-94. PMID: 18685067; PMCID: PMC2576092.
    38. Campese V, Park J. HMG-CoA reductase inhibitors and renal function. Clin J Am Soc Nephrol. 2007 Nov; 2(6):1100-3. PMID: 17942762.
      View in: PubMed
    39. Campese V. Diuretics are preferred over angiotensin II-converting enzyme inhibitors for initial therapy of uncomplicated hypertension. Am J Kidney Dis. 2007 Aug; 50(2):197-202. PMID: 17660021.
      View in: PubMed
    40. Campese V, Ye S. A vitamin-E-fortified diet reduces oxidative stress, sympathetic nerve activity, and hypertension in the phenol-renal injury model in rats. J Am Soc Hypertens. 2007 Jul-Aug; 1(4):242-50. PMID: 20409856.
      View in: PubMed
    41. Campese V, Park J. HMG-CoA reductase inhibitors and the kidney. Kidney Int. 2007 Jun; 71(12):1215-22. PMID: 17495867.
      View in: PubMed
    42. Bigazzi R, Bianchi S, Buoncristiani E, Campese V. Increased cardiovascular events in hypertensive patients with insulin resistance: a 13-year follow-up. Nutr Metab Cardiovasc Dis. 2008 May; 18(4):314-9. PMID: 17368007.
      View in: PubMed
    43. Park J, Campese V. Clinical characteristics of resistant hypertension: the importance of compliance and the role of diagnostic evaluation in delineating pathogenesis. J Clin Hypertens (Greenwich). 2007 Jan; 9(1 Suppl 1):7-12. PMID: 17215649.
      View in: PubMed
    44. Campese V, Sindhu RK, Ye S, Bai Y, Vaziri ND, Jabbari B. Regional expression of NO synthase, NAD(P)H oxidase and superoxide dismutase in the rat brain. Brain Res. 2007 Feb 23; 1134(1):27-32. PMID: 17196179.
      View in: PubMed
    45. Campese V, Park J. The kidney and hypertension: over 70 years of research. J Nephrol. 2006 Nov-Dec; 19(6):691-8. PMID: 17173239.
      View in: PubMed
    46. Campese V, Park J. Use of antagonists of aldosterone in patients with chronic kidney disease: Potential advantages and risks. J Hypertens. 2006 Nov; 24(11):2157-9. PMID: 17053534.
      View in: PubMed
    47. Ye S, Zhong H, Yanamadala S, Campese V. Oxidative stress mediates the stimulation of sympathetic nerve activity in the phenol renal injury model of hypertension. Hypertension. 2006 Aug; 48(2):309-15. PMID: 16785328.
      View in: PubMed
    48. Bigazzi R, Bianchi S, Batini V, Guzzo D, Campese V. Metabolic risk factors and markers of cardiovascular and renal damage in overweight subjects. Am J Hypertens. 2006 Apr; 19(4):426-31. PMID: 16580581.
      View in: PubMed
    49. Campese V, Mitra N, Sandee D. Hypertension in renal parenchymal disease: why is it so resistant to treatment? Kidney Int. 2006 Mar; 69(6):967-73. PMID: 16528245.
      View in: PubMed
    50. Campese V, Hadaya B, Chiu J. HMG-CoA reductase inhibitors and the kidney. Curr Hypertens Rep. 2005 Oct; 7(5):337-42. PMID: 16157074.
      View in: PubMed
    51. Sica DA, Giles TD, Black HR, Campese V. ACE inhibitors: over two decades of use. J Clin Hypertens (Greenwich). 2005 Sep; 7(9):531-7. PMID: 16227772.
      View in: PubMed
    52. Campese V, Shaohua Y, Huiquin Z. Oxidative stress mediates angiotensin II-dependent stimulation of sympathetic nerve activity. Hypertension. 2005 Sep; 46(3):533-9. PMID: 16116043.
      View in: PubMed
    53. Bianchi S, Bigazzi R, Campese V. Antagonists of aldosterone and proteinuria in patients with CKD: an uncontrolled pilot study. Am J Kidney Dis. 2005 Jul; 46(1):45-51. PMID: 15983956.
      View in: PubMed
    54. Campese V, Nadim MK, Epstein M. Are 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors renoprotective? J Am Soc Nephrol. 2005 Mar; 16 Suppl 1:S11-7. PMID: 15938026.
      View in: PubMed
    55. Epstein M, Campese V. Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors on renal function. Am J Kidney Dis. 2005 Jan; 45(1):2-14. PMID: 15696439.
      View in: PubMed
    56. Nadim MK, Dua R, Campese V. Antihypertensive drugs and the kidney. Curr Cardiol Rep. 2004 Nov; 6(6):403-8. PMID: 15485598.
      View in: PubMed
    57. Campese V, Ye S, Zhong H, Yanamadala V, Ye Z, Chiu J. Reactive oxygen species stimulate central and peripheral sympathetic nervous system activity. Am J Physiol Heart Circ Physiol. 2004 Aug; 287(2):H695-703. PMID: 15277201.
      View in: PubMed
    58. Davidson MB, Bazargan M, Bakris G, Peters Harmel A, Campese V, Basta E. ImmunoDip: an improved screening method for microalbuminuria. Am J Nephrol. 2004 May-Jun; 24(3):284-8. PMID: 15087587.
      View in: PubMed
    59. Epstein M, Campese V. Evolving role of calcium antagonists in the management of hypertension. Med Clin North Am. 2004 Jan; 88(1):149-65. PMID: 14871057.
      View in: PubMed
    60. Campese V. A new model of neurogenic hypertension caused by renal injury: pathophysiology and therapeutic implications. Clin Exp Nephrol. 2003 Sep; 7(3):167-71. PMID: 14586711.
      View in: PubMed
    61. Bianchi S, Bigazzi R, Caiazza A, Campese V. A controlled, prospective study of the effects of atorvastatin on proteinuria and progression of kidney disease. Am J Kidney Dis. 2003 Mar; 41(3):565-70. PMID: 12612979.
      View in: PubMed
    62. Yang LE, Zhong H, Leong PK, Perianayagam A, Campese V, McDonough AA. Chronic renal injury-induced hypertension alters renal NHE3 distribution and abundance. Am J Physiol Renal Physiol. 2003 May; 284(5):F1056-65. PMID: 12554635.
      View in: PubMed
    63. Yang LE, Leong PK, Ye S, Campese V, McDonough AA. Responses of proximal tubule sodium transporters to acute injury-induced hypertension. Am J Physiol Renal Physiol. 2003 Feb; 284(2):F313-22. PMID: 12388425.
      View in: PubMed
    64. Ye S, Zhong H, Yanamadala V, Campese V. Renal injury caused by intrarenal injection of phenol increases afferent and efferent renal sympathetic nerve activity. Am J Hypertens. 2002 Aug; 15(8):717-24. PMID: 12160195.
      View in: PubMed
    65. Campese V, Mozayeni P, Ye S, Gumbard M. High salt intake inhibits nitric oxide synthase expression and aggravates hypertension in rats with chronic renal failure. J Nephrol. 2002 Jul-Aug; 15(4):407-13. PMID: 12243372.
      View in: PubMed
    66. Ye S, Zhong H, Duong VN, Campese V. Losartan reduces central and peripheral sympathetic nerve activity in a rat model of neurogenic hypertension. Hypertension. 2002 Jun; 39(6):1101-6. PMID: 12052849.
      View in: PubMed
    67. Campese V, Krol E. Neurogenic factors in renal hypertension. Curr Hypertens Rep. 2002 Jun; 4(3):256-60. PMID: 12003710.
      View in: PubMed
    68. Ferrario CM, Smith RD, Brosnihan B, Chappell MC, Campese V, Vesterqvist O, Liao WC, Ruddy MC, Grim CE. Effects of omapatrilat on the renin-angiotensin system in salt-sensitive hypertension. Am J Hypertens. 2002 Jun; 15(6):557-64. PMID: 12074359.
      View in: PubMed
    69. Campese V, Ye S, Zhong H. Downregulation of neuronal nitric oxide synthase and interleukin-1beta mediates angiotensin II-dependent stimulation of sympathetic nerve activity. Hypertension. 2002 Feb; 39(2 Pt 2):519-24. PMID: 11882601.
      View in: PubMed